



# September Newsletter



Where Life-changing Therapies Turn First™

Volume 11, Issue 9

We are recruiting for CRAs in the US, Australia, UK, France, Belgium, Sweden, Germany, Poland, Italy and the Netherlands!

If you are interested in scheduling a meeting with CTI, please contact Nick Schatzman at 513-598-9290 or via email at [nschatzman@ctifacts.com](mailto:nschatzman@ctifacts.com)

## Upcoming Meetings CTI will be Attending ...

**Stem Cell Meeting on the MESA**  
San Diego, CA – October 14-16

**Society for Medical Decision Making Annual Meeting**  
Baltimore, MD – October 19-23

**American College of Rheumatology Annual Meeting**  
San Diego, CA – October 26-30

**American Association for the Study of Liver Diseases Annual Meeting**  
Washington DC – November 1-5



Some CTI employees at our 15 Year Kick-Off Party

## A Reflection On CTI's 15<sup>th</sup> Anniversary

As we begin our 15<sup>th</sup> year in business, we would like to take this opportunity to reflect on where we have come from, what we have accomplished, and acknowledge the many contributors to our success.

First, we would like to thank the 70 pharmaceutical and biotechnology companies that collaborate with CTI today. You have trusted us with more than 1200 projects since our inception, and for that we are grateful. You can choose anyone in the world to partner with, and time after time, you have chosen CTI. We would like to formally thank Astellas Pharma, Inc. (previously Fujisawa) and Genentech Roche, who believed in us the first month we opened our doors, and have continued to allow us to work with them 15 years later.

We would also like to acknowledge the support and guidance that we have received from our business partners. We are proud to say that we have been working with the same accounting firm, bank, legal team, and printing company since our inception. To Plante Moran, Fifth Third Bank, Schwartz Manes Ruby & Slovin, and Kahny Printing – from the bottom of our hearts, we say thank you.

It is important for us to acknowledge the physicians, nurses, pharmacists, and research personnel at the hospitals, medical centers, and clinics

**American Society of Nephrology**  
**Kidney Week 2013**  
Atlanta, GA – November 5-10

**World Stem Cell Summit**  
San Diego, CA – December 4- 6

**American Society of  
Hematology Annual Meeting**  
New Orleans, LA – December 7-  
10

**Congratulations to these  
recently promoted CTI  
employees:**

Matt Bobinski – Associate Study  
Manager

**Welcome the newest  
CTI employees:**

Carol Barbara – Senior Clinical  
Safety Scientist

Shelly Brewer – Director, Global  
Safety and Pharmacovigilance

Janet Williams – Assistant  
Director, Clinical Trials

**Quick Links...**

[Website](#)

[Email](#)

[Join Our Mailing List!](#)

around the world. Without you, the many advances in medical therapy and surgical procedures that we have been privileged to be a part of would have never occurred. Your dedication and hard work in the face of incredible challenges is awe-inspiring. We feel extremely fortunate to call you both friends and colleagues.

We would be remiss to not focus on the patients in our clinical research programs. Each patient unselfishly participates in clinical trials, where the outcome is very much unknown. They believe in standing upon the shoulders of the patients who have come before them, and moving the field forward. The patients are truly remarkable in the personal sacrifices they make, and it is inspirational to see the advances in medicine and disease management due to their steadfast resolve.

We would also like to thank the CTI team, which now works out of 15 states across the US and in 15 countries around the world. We are proud to work with you every day. Your hard work and dedication make us proud as you practice the "Four P's" (Passion, Persistence, Purpose, Patience) to achieve the impossible. Your record in new drug approvals is a testament to this resolve. You are truly changing lives every day. We are honored to lead you and we are humbled by the responsibilities that occur because of this. A simple thank you is not strong enough to show our gratitude for all that you do for us, our clients, research centers, and patients.

Finally, we would like to convey our optimism for the future. With advances in regenerative medicine, including cell and gene therapy, regulatory changes such as break through designation, and new focus on orphan diseases, we believe major advances will be made in diseases that are currently untreatable in the very near future, and that CTI will continue play to a significant role.

We have been extremely blessed to have this opportunity and we want to thank each and every one of you.

With sincere gratitude,



Tim Schroeder  
CEO



Lynn Fallon  
President

## About CTI

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI's focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program's success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.